Intellia Will Appoint New Chief Medical Officer
Biotech operators should note the hire as Intellia pivots toward commercializing its first gene editing product.
Updated on Oct. 13, 2026 in People
Cambridge-based Intellia Therapeutics has named Jing L. Marantz as its new Chief Medical Officer, effective October 26, 2026. Marantz brings over 25 years of biopharmaceutical experience to the gene editing firm as it shifts focus to commercialization.
Why it matters
The appointment signals a strategic move to bolster leadership for Intellia's upcoming Phase 3 trials in transthyretin amyloidosis and its broader commercial development efforts. Expanding executive capacity in medical and regulatory affairs is a common requirement as firms move from laboratory discovery toward market-ready products.
Jing L. Marantz joins the firm with more than 25 years of industry experience to lead translational, development, regulatory, and medical functions. The appointment is a key milestone as the company works to advance its pipeline toward commercial viability.
The players
Intellia Therapeutics
A Cambridge-based biotechnology company focused on the development of in vivo gene editing therapies.
Jing L. Marantz
Incoming Chief Medical Officer with a medical degree, Ph.D., and an MBA from the University of California at Berkeley.
The details
Marantz will oversee critical functions including clinical development and regulatory affairs as Intellia scales its internal operations. Her background at Scholar Rock and her current seat on the board of Arcturus Therapeutics provide experience in navigating the high-stakes transition from clinical trial participant to potential commercial drug provider.
Timeline
October 13, 2026: Appointment of Chief Medical Officer announced.
October 26, 2026: Appointment becomes effective.
Market Landscape
The hire aligns with industry trends where biotech firms prioritize specialized regulatory leadership to navigate the FDA's rigorous approval pathway for in vivo gene editing. This reflects the broader sector shift from basic research to the high-compliance requirements of late-stage commercialization.
Operators in the clinical-stage biotech space should track Intellia's upcoming Phase 3 trials as a benchmark for commercial readiness. Monitor future filings for changes in regulatory strategy that may impact downstream clinical trial timelines for similar genetic medicine firms.
The takeaway
Executive transitions at this scale often precede shifts in clinical trial deployment and regulatory focus. Managers should monitor the progress of Intellia's transthyretin amyloidosis program as a bellwether for the scalability of in vivo gene editing technology.
Further reading
For more on executive shifts, visit the People section.
